Sage Therapeutics, Inc. (SAGE) is focused on developing life-changing brain health medicines.The company’s first marketed drug, Zulresso (brexanolone), was approved by the FDA in 2019 as the first-ever FDA-approved treatment for adults with postpartum depression (PPD).SAGE’s second marketed drug, Zurzuvae (zuranolone) was approved by the FDA last August and commercially launched in December 2023. Zurzuvae is the first and only oral medicine indicated for adults with PPD.SAGE markets Zurzuvae in partnership ...